natgillin/translations-raw huggingface dataset:
Results from animal studies indicate that regorafenib can impair male and female fertility (see section 5.3).
Izsledki študij na živalih kažejo, da lahko regorafenib škodljivo vpliva na plodnost pri moških in ženskah (glejte poglavje 5.3).
Results from animal studies using 14C-labelled tigecycline indicate that tigecycline is excreted readily via the milk of lactating rats.
Rezultati študij na živalih, pri katerih so uporabljali tigeciklin, označen s 14C, kažejo, da se tigeciklin z lahkoto izloča preko mleka doječih podgan.
Results from both studies demonstrated statistically significant reduction of the risk of treatment failure in patients treated with Humira versus patients receiving placebo (See Table 22).
Rezultati iz obeh študij kažejo statistično značilno zmanjšanje tveganja za neuspeh zdravljenja pri bolnikih, ki so prejemali zdravilo Humira, v primerjavi z bolniki, ki so prejemali placebo (glejte preglednico 22).
Results from both studies demonstrated statistically significant reduction of the risk of treatment failure in patients treated with Humira versus patients receiving placebo (See Table 24).
Rezultati iz obeh študij kažejo statistično značilno zmanjšanje tveganja za neuspeh zdravljenja pri bolnikih, ki so prejemali zdravilo Humira, v primerjavi z bolniki, ki so prejemali placebo (glejte preglednico 24).
Results from both trials indicated that continued ranibizumab treatment may also be of benefit in patients who lost ≥15 letters of best-corrected visual acuity (BCVA) in the first year of treatment.
Rezultati obeh študij so pokazali, da lahko nadaljnje zdravljenje z ranibizumabom koristi tudi bolnikom, pri katerih je v prvem letu zdravljenja prišlo do poslabšanja najboljše ostrine vida s korekcijo (BCVA, best-corrected visual acuity) za ≥15 črk.
Results from clinical studies in prophylaxis of Invasive Fungal Infections
Izsledki kliničnih študij profilakse invazivnih glivnih okužb
Results from clinical studies in prophylaxis of Invasive Fungal Infections.
Izsledki kliničnih študij profilakse invazivnih glivičnih okužb
Results from clinical trials conducted with the oral antidiabetics pioglitazone, metformin and glyburide in combination with vildagliptin have shown no clinically relevant pharmacokinetic interactions in the target population.
Rezultati kliničnih preskušanjj s peroralnimi antidiabetiki pioglitazonom, metforminom in gliburidom v kombinaciji z vildagliptinom niso pokazali nobenih klinično pomembnih farmakokinetičnih interakcij pri ciljni populaciji.
Results from clinical trials performed with once-daily tacrolimus Advagraf Liver transplantation
Rezultati iz kliničnih preskušanj izvedenih z odmerjanjem takrolimusa (Advagraf) enkrat dnevno Presaditev jeter
Results from clinical trials performed with once-daily tacrolimus, Envarsus
Rezultati kliničnih preskušanj, opravljenih z zdravilom Envarsus enkrat na dan
Results from different studies show that, overall, 95.5% and 99.9% of subjects had anti-diphtheria and anti-tetanus titres 
Rezultati različnih študij kažejo, da je, gledano v celoti, en mesec po zaključku osnovnega cepljenja imelo 95,5 % oseb titer protiteles proti davici ≥ 0,1 i.e./ml.
Results from once-daily dosing with tafamidis meglumine 15, 30, or 60 mg for 14 days demonstrated dose-dependent increases in Cmax and AUC between doses of 15 mg and 30 mg and less than dose proportional between 30 and 60 mg, indicating saturation of absorption process beyond 30 mg.
Rezultati odmerjanja tafamidis meglumina v odmerkih 15, 30 ali 60 mg enkrat na dan v obdobju dni, so pokazali od odmerka odvisno zvečanje Cmax in AUC med odmerkoma 15 mg in 30 mg, med odmerkoma 30 in 60 mg pa je bilo zvečanje manjše od sorazmernega zvečanja pri tem odmerku, kar kaže na nasičenje pri procesu absorpcije odmerkov, večjih od 30 mg.
Results from patient studies showed that concomitant treatment increased the risk of the following adverse reactions: diplopia, abnormal coordination and dizziness.
Izsledki kliničnih študij pri bolnikih kažejo, da sočasno zdravljenje zveča tveganje za naslednje neželene reakcije: diplopija, nenormalna koordinacija, in omotica.
Results from post-hoc, exploratory multivariate analyses indicate that other patient and tumour characteristics (e.g.
Rezultati post-hoc eksploratornih analiz multivariat kažejo, da druge lastnosti bolnika in tumorja (npr. status telesne zmogljivosti po lestvici ECOG,
Results from studies comparing Toujeo and insulin glargine 100 units/ml did not indicate any difference in term of development of anti-insulin antibodies, on efficacy, safety or dose of basal insulin between Toujeo and insulin glargine 100 units/ml.
Rezultati študij, ki so primerjale zdravilo Toujeo z insulinom glarginom 100 enot/ml, niso pokazali razlik, kar zadeva nastanek protiinsulinskih protiteles, učinkovitost, varnost ali odmerek bazalnega insulina med zdravilom Toujeo in insulinom glarginom 100 enot/ml.
Results from studies with other HIV protease inhibitors and boceprevir suggest that co-administration of fosamprenavir/ritonavir with boceprevir is likely to lead to subtherapeutic levels of fosamprenavir and boceprevir.
Rezultati študij z drugimi zaviralci proteaz HIV in boceprevirjem kažejo, da med sočasno uporabo fosamprenavirja/ritonavirja z boceprevirjem obstaja verjetnost za subterapevtsko koncentracijo fosamprenavirja in boceprevirja.
Results from subgroup analyses in the pivotal clinical study in dialysis patients show that the concomitant use of frequently co-prescribed medications in CKD patients (fluoroquinolones, tetracyclines, proton pump inhibitors, thyroid hormones, sertraline, Vitamin D, warfarin, acetylsalicylic acid) do not affect the efficacy of Fexeric with respect to its ability to lower serum phosphorus.
Rezultati analiz podskupin v ključni klinični študiji bolnikov na dializi so pokazali, da sočasna uporaba pogostih sočasno predpisanih zdravil pri bolnikih s KLB (fluorokinolonov, tetraciklinov, zaviralcev protonske črpalke, ščitničnih hormonov, sertralina, vitamina D, varfarina, acetilsalicilne kisline) ne vplivajo na učinkovitost zdravila Fexeric glede njegove sposobnosti zniževanja ravni fosforja v serumu.
Results from the 2- and 4- week studies showed that no pharmacological tolerance developed with any dose of Sonata.
Rezultati iz 2 in 4-tedenskih raziskav kažejo, da se pri nobenem odmerku zdravila Sonata ni razvila farmakološka toleranca.
Results from the 2- and 4- week studies showed that no pharmacological tolerance developed with any dose of Zerene.
Rezultati iz 2 in 4-tedenskih raziskav kažejo, da se pri nobenem odmerku zdravila Zerene ni razvila farmakološka toleranca.
Results from the clinical field study involving 151 treated and placebo-treated dogs showed that the clinical signs of the disease (mast cell tumour) and treatment related adverse reactions are very similar in nature.
Rezultati kliničnih študij v praksi, ki so vključevale 151 zdravljenih in placebo zdravljenih psov, so pokazali, da so si klinični znaki bolezni (mastocitoma) in neželenimi učinki povezani z zdravljenjem po naravi zelo podobni.
Results from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) showed that the overall global health-related quality of life and the five functioning domains (physical, role, cognitive, emotional and social) were maintained for patients on sunitinib treatment as compared to placebo with limited adverse symptomatic effects.
Rezultati iz vprašalnika Evropske organizacije za raziskave in zdravljenje rakavih bolezni, ki se je nanašal na kakovost življenja /European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)/ so pokazali, da so se ohranili celokupna, s splošnim zdravstvenim stanjem povezana kakovost življenja in pet življenjskih področij (fizično, funkcijsko, kognitivno, čustveno in socialno) pri bolnikih, ki so se zdravili s sunitinibom, v primerjavi s placebom, z omejenimi neželenimi simptomatskimi učinki.
Results from the monotherapy study show that Victoza at a dose of 1.2 mg reduced HbA1c by 0.8 percentage points, whereas Victoza at a dose of 1.8 mg led to reductions of 1.1 percentage points.
Rezultati iz študije z enim zdravilom kažejo, da je zdravilo Victoza v odmerku 1,2 mg zmanjšalo ravni HbA1c za 0,8 odstotne točke, medtem ko je v odmerku 1,8 mg povzročilo zmanjšanje za 1,1 odstotne točke.
Results from the overall UC-II study population are shown in Table 21.
Rezultate celotne populacije v študiji UC-II prikazuje preglednica 21.
Results from the overall UC-II study population are shown in Table 23.
Rezultate celotne populacije v študiji UC-II prikazuje preglednica 23.
Results from the Phase III study (NO25026) in previously untreated patients
Rezultati študije faze III (NO25026) pri predhodno nezdravljenih bolnikih
Results from the primary analysis and the follow-up analysis are presented by Avastin Treatment and by Trial Treatment in Table 24 and Table 25, respectively.
Rezultati primarne analize in analize po spremljanju so predstavljeni glede na zdravljenje z zdravilom Avastin (preglednica 24) in glede na preizkušano zdravljenje (preglednica 25).
Results from this analysis were consistent with those from the interim analysis (Table 2, Figure 1).
Rezultati analize so bili skladni z rezultati vmesnih analiz (preglednica 2, slika 1).
Results from three other randomized trials using MabThera in combination with chemotherapy regimen other than CVP (CHOP, MCP, CHVP/Interferon-α) have also demonstrated significant improvements in response rates, time-dependent parameters as well as in overall survival.
Rezultati treh drugih randomiziranih preskušanj z uporabo zdravila MabThera v kombinaciji z drugimi shemami kemoterapije (CHOP, MCP, CHVP/interferon alfa), in ne CVP, so prav tako pokazali značilna izboljšanja deležev odgovora, od časa odvisnih parametrov in celokupnega preživetja.
Results from two clinical studies on biological effects of ingenol mebutate have shown that topical administration induced epidermal necrosis and a profound inflammatory response in both epidermis and the upper dermis of the treated skin, dominated by infiltrating T cells, neutrophils and macrophages.
Rezultati dveh kliničnih študij o bioloških učinkih ingenol mebutata so pokazali, da je topični nanos povzročil nastanek epidermalne nekroze in znaten vnetni odziv v pokožnici in zgornji usnjici zdravljene kože, pri čemer je prevladovala infiltracija limfocitov T, nevtrofilcev in makrofagov.
Results in children showed that the vast majority of those who switched treatment from stavudine or zidovudine maintained their low HIV blood levels on Viread (83% of children in the Viread group and 92% of those on stavudine or zidovudine had viral loads below 400 copies/ml after 48 weeks).
Rezultati pri otrocih so pokazali, da je večina tistih, ki so zamenjali zdravljenje s stavudinom ali zidovudinom z jemanjem zdravila Viread, ohranila nizko raven virusa HIV (83 % otrok v skupini, ki je jemala zdravilo Viread, in 92 % tistih, ki so jemali stavudin ali zidovudin, je imelo po 48 tednih virusno breme pod 400 kopij/ml).
Results indicate that less than 4 % of an orally administered pazopanib dose is excreted in the urine as pazopanib and metabolites.
Rezultati kažejo, da se manj kot 4 % peroralno uporabljenega odmerka pazopaniba izloči z urinom v obliki pazopaniba in presnovkov.
Results of 24-week (LOCFa) placebo-controlled studies of dapagliflozin in add-on combination with metformin or sitagliptin (with or without metformin)
Rezultati 24-tedenskih (LOCFa), s placebom kontroliranih študij dapagliflozina kot dodatka h kombinaciji z metforminom ali sitagliptinom (z ali brez metformina)
Results of 24-week placebo-controlled studies of dapagliflozin in add-on combination with sulphonylurea (glimepiride) or metformin and a sulphonylurea
Rezultati 24-tedenskih s placebom kontroliranih študij dapagliflozina kot dodatka h kombinaciji s sulfonilsečnino (glimepirid) ali z metforminom in sulfonilsečnino
Results of a 1 year open label safety study in 54 paediatric patients from 3 months to 16 years of age with epilepsy indicate that the adverse events of pyrexia and upper respiratory infections were observed more frequently than in adult studies (see sections 4.2, 4.8 and 5.2).
Rezultati enoletne odprte študije varnosti pri 54 pediatričnih bolnikih z epilepsijo, starih od 3 mesecev do 16 let, kažejo, da so opazili neželene učinke – pireksijo in okužbe zgornjih dihal – pogosteje kot v študijah pri odraslih (glejte poglavja 4.2, 4.8 in 5.2).
Results of a 1 year open label safety study in 54 paediatric patients from 3 months to 16 years of age with epilepsy indicate that the adverse events of pyrexia and upper respiratory infections were observed more frequently than in adult studies (see sections 4.2, 4.8 and 5.2).
Rezultatienoletne odprte študije varnostipri54 pediatričnih bolnikihz epilepsijo, starihod3 mesecevdo 16 let, kažejo, da so opazilineželene učinke –pireksijoinokužbe zgornjih dihal– pogosteje kotvštudijah pri odraslih(glejte poglavja 4.2, 4.8 in 5.2).
Results of a 48-week analysis of the South African study BI 1100.1368 confirmed that the 4/7 mg/kg and 150 mg/m2 nevirapine dose groups were well tolerated and effective in treating antiretroviral naïve paediatric patients.
Izsledki analize podatkov iz 48-tedenskega obdobja v južnoafriški raziskavi BI 1100.1368 so potrdili, da je prenašanje odmerkov nevirapina po 4/7 mg/kg in 150 mg/m2 dobro in da so bili učinkoviti v zdravljenju prvič zdravljenih pediatričnih bolnikov.
Results of a cross-study analysis suggest that the exposure to topotecan lactone, the active moiety following topotecan administration, increases at decreased renal function.
Rezultati analize navzkrižne študije so pokazali, da se izpostavljenost topotekan laktonu, aktivni komponenti topotekana, poveča ob zmanjšani ledvični funkciji.
Results of a drug-drug interaction study conducted in cancer patients demonstrated that the systemic exposure of ethinyl estradiol and norethindrone is not altered when co-administered with vismodegib.
Izsledki študije medsebojnega delovanja zdravilo-zdravilo pri bolnikih z rakom so pokazali, da sistemska izpostavljenost etinilestradiolu in noretindronu ni spremenjena, ko ju dajemo sočasno z vismodegibom.
Results of a pharmacokinetic interaction study indicated a significant 2.8-, 1.5- and 9-fold reduced AUCinf, Cmax and plasma concentration at 24 hours, respectively, after administration of Tarceva in smokers as compared to non-smokers (see section 5.2).
Izsledki študije o farmakokinetičnih interakcijah so pokazali, da so bili po aplikaciji zdravila Tarceva pri kadilcih v primerjavi z nekadilci pomembno zmanjšane AUC∞ (2,8-krat), Cmax (1,5-krat) in plazemske koncentracije po 24 urah (9-krat) (glejte poglavje 5.2).
Results of a post-hoc, exploratory multivariate analysis indicated that nivolumab-treated patients with poorer prognostic features and/or aggressive disease when combined with lower (e.g. < 50%) or no tumour PD-L1 expression may be at higher risk of death within the first 3 months.
Rezultati post-hoc eksploratorne analize multivariat so pokazali, da je pri bolnikih, ki so se zdravili z nivolumabom, in so imeli slabše prognostične dejavnike in/ali agresivno bolezen v kombinaciji z manjšo ekspresijo PD-L1 tumorja (npr. < 50 %) ali brez nje, tveganje za smrt v prvih 3 mesecih lahko večje.
Results of all pregnancy tests should be discussed with the patient.
O rezultatih vseh nosečnostnih testov se je treba pogovoriti z bolnico.
Results of an active-controlled trial of Eperzan 30 mg SC weekly (with uptitration to 50 mg weekly) versus liraglutide 1.8 mg daily at 32 weeksa
Rezultati z aktivno učinkovino kontroliranega preskušanja zdravila Eperzan 30 mg subkutano na teden (z zvišanjem na 50 mg na teden) v primerjavi z 1,8 mg liraglutida na dan po 32 tedniha
Results of an epidemiological study suggested that there was no increased risk of suicidality with aripiprazole compared to other antipsychotics among adult patients with schizophrenia or bipolar disorder.
Izsledki epidemiološke raziskave niso pokazali povečanega tveganja za samomor pri odraslih bolnikih s shizofrenijo ali z bipolarno motnjo, ki so se zdravili z aripiprazolom v primerjavi z drugimi antipsihotiki.
Results of animal reproduction studies indicate that recombinant interferon alfa-2b was not teratogenic in rats or rabbits, nor did it adversely affect pregnancy, foetal development or reproductive capacity in offspring of treated rats.
Izsledki reprodukcijskih raziskav na živalih kažejo, da rekombinantni interferon alfa-2b ni teratogen za podgane in kunce in da ne vpliva negativno na nosečnost, razvoj ploda ali reprodukcijsko sposobnost
Results of blood tests suggesting impaired liver and kidney function
rezultati krvnih preiskav, ki kažejo na oslabljeno delovanje jeter in ledvic
Results of both studies showed that the antithrombotic effect of Pradaxa 220 mg and 150 mg were statistically non-inferior to that of enoxaparin on total VTE and all-cause mortality.
Izsledki obeh raziskav so pokazali, da antitrombotični učinek zdravila Pradaxa v odmerku 220 mg in 150 mg ni statistično manjši od učinka enoksaparina, če upoštevamo skupno pojavnost trombemboličnih dogodkov in umrljivost iz vseh vzrokov.
Results of central laboratory evaluations were available for a subset of 90 patients (51 in Group A, 39 in Group B).
Rezultati ocen centralnega laboratorija so bili na voljo za 90 bolnikov (51 iz skupine A, 39 iz skupine B).
Results of environmental risk assessment studies indicated that use of JEVTANA will not cause significant risk to the aquatic environment (see section 6.6 for disposal of unused product).
Rezultati študij ocene okoljskega tveganja kažejo, da uporaba zdravila JEVTANA ne povzroča pomembnega tveganja za vodno okolje (glejte poglavje 6.6 za odlaganje neporabljenega zdravila).
Results of in vitro studies demonstrate that duloxetine does not induce the catalytic activity of CYP3A.
Rezultati študij in vitro kažejo, da duloksetin ne inducira katalitske aktivnosti CYP3A.
Results of in vitro studies showed a weak antagonism of nevirapine by
Izsledki raziskav in vitro so pokazali, da ima adefovir šibak antagonistični učinek na nevirapin (glejte poglavje 5.1).
Results of once-daily dosing with tafamidis meglumine 20 mg for 14 days demonstrated that steady- state was achieved by Day 14.
Rezultati odmerjanja tafamidis meglumina v odmerku 20 mg enkrat na dan v obdobju 14 dni so pokazali, da je bilo stanje dinamičnega ravnovesja doseženo do 14. dne.
Results of one intravenous and two short term oral tyramine challenge studies, as well as results of home monitoring of blood pressure after meals during chronic dosing in two therapeutic trials in PD patients, did not detect any clinically important increase in blood pressure.
Rezultati ene študije, v kateri so preiskovancem dajali intravenski tiramin, in dveh kratkoročnih študij s peroralno danim tiraminom ter rezultati spremljanja krvnega tlaka po obrokih v domačem okolju med kroničnim odmerjanjem v dveh terapevtskih preskušanjih pri bolnikih s parkinsonovo boleznijo kažejo, da ni prišlo do klinično pomembnega dviga krvnega tlaka.
Results of renal biopsies, if available
izvidi ledvične biopsije, če so na voljo,
Results of studies compared to standard of care (SOC) in non-splenectomised patients
Rezultati študij v primerjavi s standardno oskrbo pri nesplenektomiranih bolnikih
Results of study 304 indicate that skeletal improvements are maintained or continue to improve during at least 4 years of treatment with Cerdelga.
Rezultati študije 304 kažejo, da se skeletna izboljšanja ohranijo ali se še naprej izboljšujejo v teku vsaj 4 let zdravljenja z zdravilom Cerdelga.
Results of subgroup analyses were in general consistent with the results seen in the FL population, supporting the robustness of the overall result.
Rezultati analiz podskupin so se na splošno skladali z rezultati v populaciji s FL; to potrjuje robustnost skupnega rezultata.
Results of the Ames/salmonella and Human Peripheral Blood Lymphocyte (HPBL) chromosome aberration tests showed a positive mutagenicity response.
Rezultati testa Ames/Salmonella in testa kromosomskih aberacij v človeških limfocitih iz periferne krvi (HPBL – »Human Peripheral Blood Lymphocyte«) so pokazali pozitiven mutageni odziv.
Results of the Ames/salmonella and Human Peripheral Blood Lymphocyte (HPBL) chromosome aberration tests showed a positive mutagenicity response.
Rezultati testa Ames/Salmonella in testa kromosomskih aberacij v človeških limfocitih periferne krvi (HPBL – »Human Peripheral Blood Lymphocyte«) so pokazali pozitiven mutageni odziv.
Results of the Ames/salmonella and Human Peripheral Blood Lymphocyte (HPBL) chromosome aberration tests showed a positive mutagenicity response.
Rezultati testa po Ames/Salmonella in testa kromosomskih aberacij v človeških limfocitih iz periferne krvi (HPBL – »Human Peripheral Blood Lymphocyte«) so pokazali pozitiven mutageni odziv.
Results of the cytogenetic response and HRQoL were consistent with the findings of the primary endpoint and in favour of lenalidomide treatment compared to placebo.
Rezultati citogenetskega odziva in HRQoL so bili skladni z rezultati primarnega končnega cilja in so kazali v korist zdravljenja z lenalidomidom v primerjavi s placebom.
Results of the studies also showed that patients who have compensated cirrhosis (scarring of the liver but who maintained liver function) had a higher likelihood of clearing the virus when treatment was extended to 24 weeks.
Rezultati študij so pokazali tudi, da je bila pri bolnikih s kompenzirano cirozo (brazgotinjenjem jeter, vendar brez odpovedi njihovega delovanja) verjetnost uničenja virusa večja, kadar je bilo zdravljenje podaljšano na 24 tednov.
Results of the study showed Imbruvica to be effective, with around 68% of patients having either a complete or partial response to treatment: 21% of patients had a complete response (i.e. disappearance of all signs of cancer) and 47% had a partial response (i.e. the patient improved but some signs of the disease remained).
Rezultati študije so pokazali, da je zdravilo Imbruvica učinkovito, saj je približno 68 % bolnikov izkazalo popoln ali delen odziv na zdravljenje: pri 21 % bolnikov je bil odziv popoln (tj. izginotje vseh znakov raka po zdravljenju), pri 47 % pa je bil odziv delen (tj. bolnikovo stanje se je izboljšalo, vendar so nekateri znaki bolezni ostali).
Results of these analyses subsequently led to an unblinding in both studies, in order to allow patients in the placebo/dexamethasone group to receive treatment with the lenalidomide/dexamethasone combination.
Rezultati teh analiz so kasneje privedli do razkritja podatkov v obeh študijah, da bi bolniki v skupini, ki je prejemala placebo/deksametazon, lahko prejemali zdravljenje s kombinacijo lenalidomid/deksametazon.
Results of these studies showed that pigs immunised with Improvac showed little reaction to the act of injection.
Rezultati teh študij so pokazali, da je pri cepljenih prašičih malo reakcij na injiciranje in malo reakcij na mestu injiciranja.
Results of this study indicated that axitinib plasma exposures up to two-fold greater than therapeutic levels expected following a 5 mg dose, did not produce clinically-significant QT interval prolongation.
Rezultati te študije so pokazali, da izpostavljenosti plazemskim koncentracijam aksitiniba, ki so za do dvakrat presegale pričakovane terapevtske koncentracije po 5 mg odmerku, niso povzročile klinično pomembnega podaljšanja intervala QT.
Results of this study showed that Benepali is as effective as Enbrel at reducing symptoms of rheumatoid arthritis: 78% of patients given Benepali (193 out of 247) achieved at least a 20% reduction in ACR scores after 24 weeks of treatment, compared with 80% of patients given Enbrel (188 out of 234).
Rezultati te študije so pokazali, da je zdravilo Benepali pri zmanjševanju simptomov revmatoidnega artritisa enako učinkovito kot zdravilo Enbrel: po 24 tednih zdravljenja je prišlo do vsaj 20-odstotnega zmanjšanja vrednosti ACR pri 78 % (193 od 247) bolnikov, ki so prejeli zdravilo Benepali, in pri 80 % (188 od 234) bolnikov, ki so prejeli zdravilo Enbrel.